JNJ

223.85

-1.59%↓

UNH

369.78

+0.21%↑

TMO

463.84

-1.16%↓

ISRG

450.1

-1.64%↓

ABT

87.4

-2.36%↓

JNJ

223.85

-1.59%↓

UNH

369.78

+0.21%↑

TMO

463.84

-1.16%↓

ISRG

450.1

-1.64%↓

ABT

87.4

-2.36%↓

JNJ

223.85

-1.59%↓

UNH

369.78

+0.21%↑

TMO

463.84

-1.16%↓

ISRG

450.1

-1.64%↓

ABT

87.4

-2.36%↓

JNJ

223.85

-1.59%↓

UNH

369.78

+0.21%↑

TMO

463.84

-1.16%↓

ISRG

450.1

-1.64%↓

ABT

87.4

-2.36%↓

JNJ

223.85

-1.59%↓

UNH

369.78

+0.21%↑

TMO

463.84

-1.16%↓

ISRG

450.1

-1.64%↓

ABT

87.4

-2.36%↓

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

165.57 -0.4

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

164.7

Massimo

166.47

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+19.01% upside

Dividendi

By Dow Jones

Utili prossimi

7 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

508M

8.4B

Apertura precedente

165.97

Chiusura precedente

165.57

Notizie sul Sentiment di mercato

By Acuity

75%

25%

322 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 mag 2026, 23:47 UTC

Utili

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

3 mag 2026, 22:35 UTC

Utili

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

3 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Edge Higher Amid Signs of Resilience -- Market Talk

3 mag 2026, 23:34 UTC

Discorsi di Mercato

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

3 mag 2026, 23:32 UTC

Utili

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

3 mag 2026, 23:30 UTC

Discorsi di Mercato

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

3 mag 2026, 23:20 UTC

Discorsi di Mercato

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

3 mag 2026, 23:16 UTC

Acquisizioni, Fusioni, Takeovers

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

3 mag 2026, 22:57 UTC

Acquisizioni, Fusioni, Takeovers

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

3 mag 2026, 22:57 UTC

Acquisizioni, Fusioni, Takeovers

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

3 mag 2026, 22:57 UTC

Acquisizioni, Fusioni, Takeovers

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

3 mag 2026, 22:57 UTC

Acquisizioni, Fusioni, Takeovers

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

3 mag 2026, 22:57 UTC

Acquisizioni, Fusioni, Takeovers

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

3 mag 2026, 22:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 mag 2026, 22:45 UTC

Discorsi di Mercato

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

3 mag 2026, 22:20 UTC

Utili

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

3 mag 2026, 22:08 UTC

Utili

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

3 mag 2026, 22:05 UTC

Utili

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

3 mag 2026, 22:05 UTC

Utili

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

3 mag 2026, 22:05 UTC

Utili

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

3 mag 2026, 22:04 UTC

Utili

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

3 mag 2026, 22:03 UTC

Utili

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

3 mag 2026, 22:03 UTC

Utili

NAB 1H Cash Return on Equity 8.5%>NAB.AU

3 mag 2026, 22:02 UTC

Utili

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

3 mag 2026, 22:02 UTC

Utili

NAB 1H Cash Earnings A$2.64B>NAB.AU

3 mag 2026, 22:02 UTC

Utili

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

3 mag 2026, 22:01 UTC

Utili

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

3 mag 2026, 22:01 UTC

Utili

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

3 mag 2026, 22:01 UTC

Utili

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

3 mag 2026, 15:06 UTC

Utili

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

19.01% in crescita

Previsioni per 12 mesi

Media 197.3 USD  19.01%

Alto 235 USD

Basso 160 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

322 / 347 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat